Veru Inc. · NASDAQ:VERU
Veru — Obesity Week 2026
15 slides from Veru's conference presentation, Nov 16, 2026
Slide 1: Enobosarm in Older Patients (≥65) with Obesity on Semaglutide
Enobosarm in Older Patients (≥65 years) with Obesity on Semaglutide: Quality Weight Loss & Better Physical Function Phase 2 QUALITY Clinical Study Post-hoc Subset Analysis K. Gary Barnette, PhD, CSO, Veru Inc. Obesity Week 16 November 2026 VERU INC. | NASDAQ: VERU MIAMI, FLORIDA
Slide 2: Weight loss on GLP-1 therapy can cost older adults function
Weight loss on GLP-1 therapy can cost older adults function Lean mass is lost Older adults have the least Stairs test real-world reserve function Part of the weight lost on semaglutide Losing muscle at 65+ puts mobility Time to climb, and power generated, is lean mass, not just fat. and independence
Slide 3: Completed Phase 2b QUALITY clinical trial study in 2025
PHASE 2b QUALITY TRIAL Completed Phase 2b QUALITY clinical trial study in 2025 Evaluated enobosarm in 168 patients with obesity Active weight loss Maintenance Primary endpoint (16 weeks) Sample size calculation Lean body mass measured by DXA scan Enobosarm 6 mg PO • n=168 patients Enobosarm 6 mg PO
Slide 4: Stair climb test
PHYSICAL FUNCTION Stair climb test1,2 Stair climb power (Watts)= (Body weight + load carried (kg)) X 9.81 m/s2 X total stair rise (m) time (s) 1. Travison TG et al. J Geront A Biol Sci Med Sci 10:1090, 2011| 2 Gagliano-Juca T. et al. J Gerontol A Biol Sci Med Sci 75:1167-1175, 2020
Slide 5: Older patients started slower and weaker on the stairs
BASELINE STAIR CLIMB BY AGE FROM PHASE 2b QUALITY CLINICAL STUDY Older patients started slower and weaker on the stairs 60 to <65 65 to <70 ≥70 n=72 n=57 n=35 Stair climb time Stair climb time Stair climb time 5.58 (2.34) s 6.24 (2.18) s 6.90 (4.16) s Stair climb power Stair climb power Stair climb
Slide 6: Post-hoc Analysis: Patients 65 and older, 3 mg vs placebo, at Day 112
Methods Post-hoc Analysis: Patients 65 and older, 3 mg vs placebo, at Day 112 Item Detail Trial V2000101 Phase 2b, Double-Blind, Randomized, Placebo-Controlled QUALITY Study Treatment All subjects received semaglutide in accordance with the approved prescribing instructions Comparison (post-hoc anal
Slide 7: Age ≥65: Enobosarm 3 mg kept lean mass while losing the same fat
BODY COMPOSITION · DAY 112 Age ≥65: Enobosarm 3 mg kept lean mass while losing the same fat as placebo in this short 16 week-study Total lean mass Total fat mass Enobosarm 3 mg +0.3 kg Enobosarm 3 mg −3.5 kg Placebo −2.0 kg Placebo −3.4 kg Adjusted difference = +2.3 kg on 3 mg, p=0.0001 No differenc
Slide 8: Age ≥65: On enobosarm 3 mg, patients climbed 15% faster than baseline
STAIR CLIMB TIME · DAY 112 Age ≥65: On enobosarm 3 mg, patients climbed 15% faster than baseline % faster than baseline (ANCOVA LS mean, adjusted for baseline time) Enobosarm 3 mg 15.1% 24x difference in time ∆ (relative difference) Placebo 0.6% Difference, 3 mg − placebo Median % change Change in s
Slide 9: Age ≥65: 3 mg patients gained power despite losing weight
STAIR CLIMB POWER · DAY 112 Age ≥65: 3 mg patients gained power despite losing weight Change in stair climb power, watts (ANCOVA LS mean, adjusted for baseline) Enobosarm 3 mg +38.4 W 29x difference in power ∆ (relative difference) Placebo +1.3 W Difference, 3 mg − placebo Median change in watts Med
Slide 10: Age ≥65: Far fewer 3 mg patients lost stair function
RESPONDER ANALYSIS · DAY 112 Age ≥65: Far fewer 3 mg patients lost stair function Got slower (any increase in time) Lost ≥10% of stair power 3 mg 12% (3/26) 3 mg 0% (0/26) Placebo 42% Placebo 42% Placebo 11/26. Fisher p=0.027; adjusted OR 0.17, p=0.021 Placebo 11/26. Fisher p<0.001 Age ≥65; implausi
Slide 11: Physical function benefit with enobosarm appears greater with age
EFFECT BY AGE · ALL AGES, 3 MG VS PLACEBO The physical function benefit with enobosarm treatment appears to be greater with age Age n per arm Stair time, 3 mg − placebo Lost ≥10% power, 3 mg vs placebo 65–69 17 / 17 −8.4% 0% vs 41% (p=0.007) 70 and over 9/9 −24.7% 0% vs 44% (p=0.08) Amount enobosarm
Slide 12: Conclusions
CONCLUSIONS Question 1 • Does rapid weight loss (with GLP-1 therapy) cause clinically relevant reduction in physical function in older patients (≥65 years of age)? Answer • Yes, the following observations are made: • While you would expect patients that lose weight to go up the steps faster, 42% of
Slide 13: Conclusions
CONCLUSIONS Question 2 • Does enobosarm 3 mg preserve physical function (stair climb) in older patients (≥65 years of age) over 16 weeks? Answer • Yes, the following observations are made: • The proportion of subjects that were slower going up the stairs was significantly lower in the enobosarm grou
Slide 14: Phase 2b PLATEAU clinical study design - Fully enrolled
TRIAL DESIGN Phase 2b PLATEAU clinical study design* - Fully enrolled Double blind study to evaluate enobosarm 3 mg on total body weight, body composition (DEXA), physical function, and safety in 239 older patients with obesity taking semaglutide for weight reduction Study duration is 68-week, Doubl
Slide 15: < o = rt 0) me} &
< o = rt 0) me} & 7